FDA issues warning letter to Balaji Amines over product misuse

Regulatory & Legal View source PDF Explain this filing

BALAMINES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹2122.10

prior close

₹2049.50

announcement price

In-mkt

timing

Nifty Microcap 250market-1.3%-1.8% vs market

Specialty Chemicals peers, median of 99sector-1.1%-2.0% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 2.0 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.3

15m

-0.4

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-1.3-1.8-1.1-2.0

Next day

-7.6-1.3-6.3-1.5-6.1

+7.0+0.0+7.0+0.3+6.7

+1.2-0.2+1.4+0.4+0.7

-1.7-3.0+1.3-2.0+0.3

-3.4-2.7-0.7-2.4-1.1

-1.7-1.7-0.0-1.3-0.4

15d

-14.9-8.9-6.1-8.6-6.4

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 99Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Balaji Amines received a warning letter from FDA Pune dated 10 Jan 2025. The FDA found a technical-grade Propylene Glycol consignment sold for industrial use was resold and used for pharmaceutical purposes, breaching the Drugs and Cosmetics Act, 1940. No penalty or adverse order was imposed. The company says there is no material impact and has tightened its end-use declaration practices. The disclosure was made late after an SEBI letter dated 29 Sept 2026.

Likely market impact

No financial or operational impact reported and no penalty imposed, but the delayed disclosure and ongoing regulatory scrutiny may affect investor confidence.